Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol 2010 Oct;56(4):329-35
Date
06/10/2010Pubmed ID
20531214Pubmed Central ID
PMC3071608DOI
10.1097/FJC.0b013e3181e96e0cScopus ID
2-s2.0-77958468395 (requires institutional sign-in at Scopus site) 50 CitationsAbstract
Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic acid and EETs have a number of beneficial cardiovascular actions. This has led to the concept that EETs and its metabolic pathway can be therapeutically targeted for hypertension and other cardiovascular diseases. One approach has been to prevent the conversion of EETs to their inactive diols by inhibiting the soluble epoxide hydrolase (sEH) enzyme. Inhibition of sEH has been demonstrated to decrease blood pressure in certain experimental models of hypertension, decrease inflammation, and protect organs from damage associated with hypertension and other cardiovascular diseases. The development of sEH inhibitors has reached the point where they are being evaluated in humans. A second therapeutic approach has been to develop EET agonists. EET agonists have been essential for determining the structure function relationship for EETs and determining cell-signaling mechanisms by which EETs exert their cardiovascular actions. More recently, EET agonists have been administered chronically to experimental animal models of hypertension and metabolic syndrome and have been demonstrated to decrease blood pressure, improve insulin signaling, and improve vascular function. These experimental findings provide evidence for sEH inhibitors and EET agonists as a therapeutic approach for cardiovascular diseases, hypertension, and the associated end-organ damage.
Author List
Imig JDMESH terms used to index this publication - Major topics in bold
AnimalsEicosanoids
Epoxide Hydrolases
Epoxy Compounds
Humans
Hypertension
Molecular Targeted Therapy
